349 related articles for article (PubMed ID: 25008478)
1. The intra-individual variability of faecal calprotectin: a prospective study in patients with active ulcerative colitis.
Lasson A; Stotzer PO; Öhman L; Isaksson S; Sapnara M; Strid H
J Crohns Colitis; 2015 Jan; 9(1):26-32. PubMed ID: 25008478
[TBL] [Abstract][Full Text] [Related]
2. Clinical importance of faecal calprotectin variability in inflammatory bowel disease: intra-individual variability and standardisation of sampling procedure.
Kristensen V; Malmstrøm GH; Skar V; Røseth A; Moum B
Scand J Gastroenterol; 2016; 51(5):548-55. PubMed ID: 26634305
[TBL] [Abstract][Full Text] [Related]
3. High within-day variability of fecal calprotectin levels in patients with active ulcerative colitis: what is the best timing for stool sampling?
Calafat M; Cabré E; Mañosa M; Lobatón T; Marín L; Domènech E
Inflamm Bowel Dis; 2015 May; 21(5):1072-6. PubMed ID: 25793326
[TBL] [Abstract][Full Text] [Related]
4. Prediction of endoscopic disease activity in ulcerative colitis by two different assays for fecal calprotectin.
Kristensen V; Klepp P; Cvancarova M; Røseth A; Skar V; Moum B
J Crohns Colitis; 2015 Feb; 9(2):164-9. PubMed ID: 25518057
[TBL] [Abstract][Full Text] [Related]
5. The value of fecal calprotectin as a marker of intestinal inflammation in patients with ulcerative colitis.
Önal İK; Beyazit Y; Şener B; Savuk B; Özer Etık D; Sayilir A; Öztaş E; Torun S; Özderın Özın Y; Tunç Demırel B; Ülker A; Dağli Ü
Turk J Gastroenterol; 2012; 23(5):509-14. PubMed ID: 23161295
[TBL] [Abstract][Full Text] [Related]
6. Accuracy of fecal calprotectin for the prediction of endoscopic activity in patients with inflammatory bowel disease.
Jusué V; Chaparro M; Gisbert JP
Dig Liver Dis; 2018 Apr; 50(4):353-359. PubMed ID: 29396129
[TBL] [Abstract][Full Text] [Related]
7. Rapid Fecal Calprotectin Test and Symptom Index in Monitoring the Disease Activity in Colonic Inflammatory Bowel Disease.
Puolanne AM; Kolho KL; Alfthan H; Ristimäki A; Mustonen H; Färkkilä M
Dig Dis Sci; 2017 Nov; 62(11):3123-3130. PubMed ID: 28948412
[TBL] [Abstract][Full Text] [Related]
8. Faecal calprotectin assay after induction with anti-Tumour Necrosis Factor α agents in inflammatory bowel disease: Prediction of clinical response and mucosal healing at one year.
Guidi L; Marzo M; Andrisani G; Felice C; Pugliese D; Mocci G; Nardone O; De Vitis I; Papa A; Rapaccini G; Forni F; Armuzzi A
Dig Liver Dis; 2014 Nov; 46(11):974-9. PubMed ID: 25096964
[TBL] [Abstract][Full Text] [Related]
9. Validation of a point-of-care desk top device to quantitate fecal calprotectin and distinguish inflammatory bowel disease from irritable bowel syndrome.
Sydora MJ; Sydora BC; Fedorak RN
J Crohns Colitis; 2012 Mar; 6(2):207-14. PubMed ID: 22325175
[TBL] [Abstract][Full Text] [Related]
10. Comparison of three commercial fecal calprotectin ELISA test kits used in patients with Inflammatory Bowel Disease.
Mirsepasi-Lauridsen HC; Bachmann Holmetoft U; Ingdam Halkjær S; Angeliki Krogfelt K; Munk Petersen A
Scand J Gastroenterol; 2016; 51(2):211-7. PubMed ID: 26359672
[TBL] [Abstract][Full Text] [Related]
11. Assessing the Correlation of Fecal Calprotectin and the Clinical Disease Activity Index in Patients With Ulcerative Colitis.
Amiriani T; Besharat S; Dadjou M; Roshandel G; Mirkarimi H; Salamat F; Joshaghani H
Gastroenterol Nurs; 2018; 41(3):201-205. PubMed ID: 29847394
[TBL] [Abstract][Full Text] [Related]
12. Faecal chitinase 3-like 1 is a reliable marker as accurate as faecal calprotectin in detecting endoscopic activity in adult patients with inflammatory bowel diseases.
Buisson A; Vazeille E; Minet-Quinard R; Goutte M; Bouvier D; Goutorbe F; Pereira B; Barnich N; Bommelaer G
Aliment Pharmacol Ther; 2016 May; 43(10):1069-79. PubMed ID: 26953251
[TBL] [Abstract][Full Text] [Related]
13. Fecal calprotectin and the clinical activity index are both useful to monitor medical treatment in patients with ulcerative colitis.
Burri E; Beglinger C; von Felten S; Lehmann FS
Dig Dis Sci; 2015 Feb; 60(2):485-91. PubMed ID: 25344905
[TBL] [Abstract][Full Text] [Related]
14. Low fecal calprotectin predicts sustained clinical remission in inflammatory bowel disease patients: a plea for deep remission.
Mooiweer E; Severs M; Schipper ME; Fidder HH; Siersema PD; Laheij RJ; Oldenburg B
J Crohns Colitis; 2015 Jan; 9(1):50-5. PubMed ID: 25518048
[TBL] [Abstract][Full Text] [Related]
15. Rapid faecal tests for detecting disease activity in colonic inflammatory bowel disease.
Puolanne AM; Kolho KL; Alfthan H; Ristimäki A; Mustonen H; Färkkilä M
Eur J Clin Invest; 2016 Oct; 46(10):825-32. PubMed ID: 27438629
[TBL] [Abstract][Full Text] [Related]
16. Comparison of two immunoassays for measurement of faecal calprotectin in detection of inflammatory bowel disease: (pre)-analytical and diagnostic performance characteristics.
Oyaert M; Trouvé C; Baert F; De Smet D; Langlois M; Vanpoucke H
Clin Chem Lab Med; 2014 Mar; 52(3):391-7. PubMed ID: 24114912
[TBL] [Abstract][Full Text] [Related]
17. FECAL CALPROTECTIN: levels for the ethiological diagnosis in Brazilian patients with gastrointestinal symptoms.
Kotze LM; Nisihara RM; Marion SB; Cavassani MF; Kotze PG
Arq Gastroenterol; 2015; 52(1):50-4. PubMed ID: 26017083
[TBL] [Abstract][Full Text] [Related]
18. Effect of faecal calprotectin assay variability on the management of inflammatory bowel disease and potential role of faecal S100A12.
Whitehead SJ; Ford C; Gama RM; Ali A; McKaig B; Waldron JL; Steed H; Brookes MJ
J Clin Pathol; 2017 Dec; 70(12):1049-1056. PubMed ID: 28735301
[TBL] [Abstract][Full Text] [Related]
19. Calprotectin is a stronger predictive marker of relapse in ulcerative colitis than in Crohn's disease.
Costa F; Mumolo MG; Ceccarelli L; Bellini M; Romano MR; Sterpi C; Ricchiuti A; Marchi S; Bottai M
Gut; 2005 Mar; 54(3):364-8. PubMed ID: 15710984
[TBL] [Abstract][Full Text] [Related]
20. [Clinical significance of faecal calprotectin levels in patients with ulcerative colitis].
Hanai H; Tozawa K; Takeuchi K; Iida T; Arai H; Kanaoka S; Sugimoto K; Yoshida K; Iwasaki T; Nakamura A; Hosoda Y; Shirai N; Hirasawa K; Takahira K; Kataoka H; Sano M; Osawa M; Sugimoto S
Nihon Shokakibyo Gakkai Zasshi; 2003 Jan; 100(1):21-7. PubMed ID: 12601924
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
